In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies to produce Victoza, also known as liraglutide, following a proposal by the ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

New year, new Veeda. The India-based CRO formerly known as Veeda Group has kicked off 2025 with a brand makeover.

Astellas Pharma and Endo subsidiary Endo USA issued voluntary recalls for products they manufacture over concerns of empty tablets and unapproved ingredients, respectively. | Astellas Pharma and Endo ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

Academics are calling for governments to act to “safeguard the ind | Academics are calling for governments to act to “safeguard the independence” of patient groups that receive funding from biopharma ...